Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer

Journal of Molecular Medicine

Volumn 93, Issue 6, 2015, Pages 619-631

  Kristian, Sascha A ^a,c   Hwang, John H ^b,c   Hall, Bradley ^a   Leire, Emma ^c   Iacomini, John ^e   Old, Robert ^f   Galili, Uri ^g   Roberts, Charles ^a,f   Mullis, Kary B ^a   Westby, Mike ^a,f   Nizet, Victor ^c,d  

^a Altermune Technologies   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DAVY FARADAY RESEARCH LABORATORY   (United Kingdom)

^g UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Anti Gal; Antibiotic therapy; Antibodies; Aptamer; Drug development; Galactose 1,3 galactosyl 1,4 N acetyl glucosamine; Group A Streptococcus; M protein; Phagocytosis; Gal

Indexed keywords

ANTIINFECTIVE AGENT; APTAMER; BACTERIUM ANTIBODY; EPITOPE; N ACETYLGLUCOSAMINE;

ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHAGOCYTOSIS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS;

ACETYLGLUCOSAMINE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; DRUG DISCOVERY; EPITOPES; HUMANS; MOLECULAR SEQUENCE DATA; PHAGOCYTOSIS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS;

EID: 84937763062     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-015-1280-4     Document Type: Article

References (41)

1. Chan M (2012) Antimicrobial resistance in the European Union and the world. Combating antimicrobial resistance: time for action Copenhagen, Denmark
2. Prevention CfDCa (2013) Antibiotic resistance threats in the United States, 2013
3. Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D, Infectious Diseases Society of America (2013) 10 x '20 Progress–development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685–1694
4. Pucci MJ, Bush K (2013) Investigational antimicrobial agents of 2013. Clin Microbiol Rev 26:792–821
5. Oleksiewicz MB, Nagy G, Nagy E (2012) Anti-bacterial monoclonal antibodies: back to the future? Arch Biochem Biophys 526:124–131
6. Scully IL, Liberator PA, Jansen KU, Anderson AS (2014) Covering all the bases: preclinical development of an effective Staphylococcus aureus vaccine. Front Immunol 5:109
7. Ahmad TA, El-Sayed LH, Haroun M, Hussein AA, El Ashry el SH (2012) Development of immunization trials against Klebsiella pneumoniae. Vaccine 30:2411–2420
8. Garcia-Quintanilla M, Pulido MR, McConnell MJ (2013) First steps towards a vaccine against Acinetobacter baumannii. Curr Pharm Biotechnol 14:897–902
9. Priebe GP, Goldberg JB (2014) Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines 13:507–519
10. Ter Meulen J (2011) Monoclonal antibodies in infectious diseases: clinical pipeline in 2011. Infect Dis Clin North Amer 25:789–802
11. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM (1988) Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 56:1730–1737
12. Galili U, Rachmilewitz EA, Peleg A, Flechner I (1984) A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med 160:1519–1531
13. Galili U, Anaraki F, Thall A, Hill-Black C, Radic M (1993) One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 82:2485–2493
14. Galili U (1993) Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 14:480–482
15. Macher BA, Galili U (2008) The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta 1780:75–88
16. Banerjee J, Nilsen-Hamilton M (2013) Aptamers: multifunctional molecules for biomedical research. J Mol Med 91:1333–1342
17. Zimbres FM, Tarnok A, Ulrich H, Wrenger C (2013) Aptamers: novel molecules as diagnostic markers in bacterial and viral infections? BioMed Res Intl 2013:731516
18. Sundaram P, Kurniawan H, Byrne ME, Wower J (2013) Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci 48:259–271
19. Carapetis JR, Steer AC, Mulholland EK, Weber M (2005) The global burden of group A streptococcal diseases. Lancet Infect Dis 5:685–694
20. Hamula CL, Le XC, Li XF (2011) DNA aptamers binding to multiple prevalent M-types of Streptococcus pyogenes. Analyt Chem 83:3640–3647
21. Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acid Res 31:3406–3415
22. Kikin O, D'Antonio L, Bagga PS (2006) QGRS Mapper: a web-based server for predicting G-quadruplexes in nucleotide sequences. Nucleic Acids Res 34:W676–W682
23. Cretin N, Iacomini J (2002) Immunoglobulin heavy chain transgenic mice expressing Galalpha(1,3)Gal-reactive antibodies. Transplantation 73:1558–1564
24. Galili U, Anaraki F (1995) alpha-galactosyl (Galalpha1-3Galbeta1-4GlcNAc-R) epitopes on human cells: synthesis of the epitope on human red cells by recombinant primate α1,3galactosyltransferase expressed in E.coli. Glycobiology 5:775–782
25. Kristian SA, Datta V, Weidenmaier C, Kansal R, Fedtke I, Peschel A, Gallo RL, Nizet V (2005) D-alanylation of teichoic acids promotes group a streptococcus antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion. J Bacteriol 187:6719–6725
26. Walker MJ, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, Henningham A, McArthur JD, Dinkla K, Aziz RK, Kansal RG et al (2007) DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med 13:981–985
27. Aziz RK, Kotb M (2008) Rise and persistence of global M1T1 clone of Streptococcus pyogenes. Emerg Infect Dis 14:1511–1517
28. Hollingshead SK, Fischetti VA, Scott JR (1987) A highly conserved region present in transcripts encoding heterologous M proteins of group A streptococci. Infect Immun 55:3237–3239
29. Oehmcke S, Shannon O, Morgelin M, Herwald H (2010) Streptococcal M proteins and their role as virulence determinants. Clin Chim Acta 411:1172–1180
30. Smeesters PR, McMillan DJ, Sriprakash KS (2010) The streptococcal M protein: a highly versatile molecule. Trends Microbiol 18:275–282
31. Crater DL, van de Rijn I (1995) Hyaluronic acid synthesis operon (has) expression in group A streptococci. J Biol Chem 270:18452–18458
32. Unnikrishnan M, Cohen J, Sriskandan S (1999) Growth-phase-dependent expression of virulence factors in an M1T1 clinical isolate of Streptococcus pyogenes. Infect Immun 67:5495–5499
33. Salvadori LG, Blake MS, McCarty M, Tai JY, Zabriskie JB (1995) Group A streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. J Infect Dis 171:593–600
34. Dale JB (2008) Current status of group A streptococcal vaccine development. Adv Exper Med Biol 609:53–63
35. Pestourie C, Tavitian B, Duconge F (2005) Aptamers against extracellular targets for in vivo applications. Biochimie 87:921–930
36. Zipfel PF, Hallstrom T, Riesbeck K (2013) Human complement control and complement evasion by pathogenic microbes—tipping the balance. Mol Immunol 56:152–160
37. McEnaney PJ, Parker CG, Zhang AX, Spiegel DA (2012) Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem Biol 7:1139–1151
38. Li J, Zacharek S, Chen X, Wang J, Zhang W, Janczuk A, Wang PG (1999) Bacteria targeted by human natural antibodies using α-Gal conjugated receptor-specific glycopolymers. Bioorg Med Chem 7:1549–1558
39. Kaewsapsak P, Esonu O, Dube DH (2013) Recruiting the host's immune system to target Helicobacter pylori's surface glycans. ChemBioChem 14:721–726
40. Bertozzi CB, Bednarski MD (1992) A receptor-mediated immune response using synthetic glycoconjugates. J Am Chem Soc 114:5543–5546
41. Krishnamurthy VM, Quinton LJ, Estroff LA, Metallo SJ, Isaacs JM, Mizgerd JP, Whitesides GM (2006) Promotion of opsonization by antibodies and phagocytosis of Gram-positive bacteria by a bifunctional polyacrylamide. Biomaterials 27:3663–3674